Ozagrel compound, preparation method and pharmaceutical composition of ozagrel compound

Abstract

The invention belongs to the technical field of medicines, and particularly relates to an ozagrel compound, a preparation method and a pharmaceutical composition of the ozagrel compound. The X-ray powder diffraction spectrogram obtained by Cu-K alpha-ray measurement is shown in a figure 1; and the structural formula is as shown in a formula (I). The ozagrel compound is a novel crystal form which is different from that in the prior art. The novel crystal form ozagrel compound has humidity, temperature and illumination stability obviously superior to those of the ozagrel in the prior art; sodium ozagrel for injection, prepared from the ozagrel compound of such crystal form, is high in redissolving performance, and insoluble particles have smaller change after an injection solution is combined; after redissolving, the contents of specific impurities I and II in the solution are obviously less than those in the prior art.

Description

technical field

[0001] The invention belongs to the technical field of medicine, and in particular relates to an ozagrel compound, a preparation method and a pharmaceutical composition thereof. Background technique

[0002] Thrombotic disease is one of the main diseases that endanger human life and health, especially cardiovascular and cerebrovascular diseases. The death rate caused by cardiovascular and cerebrovascular diseases in the world has been ranked second in the total death population, and it is expected to rise to the first place by 2020. The morbidity and mortality of cardiovascular and cerebrovascular diseases in my country are increasing year by year. According to statistics, there are more than 2 million new cerebral embolism and heart embolism patients in my country every year.

[0003] Ozagrel is a new type of anti-platelet aggregation drug. It is the first specific thromboxane synthase A2 (TXA2) inhibitor launched by Ono Pharmaceutical Co., Ltd. in Japan un...

Images